

List of Publications Prof. Oliver Cornely 2012 - 2017

1. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, **Cornely OA**, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB, Modify I, Investigators MI. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med. 2017;376(4):305-17.
2. Vehreschild JJ, Heussel CP, Groll AH, Vehreschild MJ, Silling G, Wurthwein G, Brecht M, **Cornely OA**. Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis. European radiology. 2017.
3. Solano C, Slavin M, Shaul AJ, Marks DI, Cordonnier C, **Cornely OA**, Pagliuca A, Cragin L, Jarque I, Garcia-Vidal C, Sorensen S, Vanness DJ, Charbonneau C, Barrueta JA, Peral C, De Salas-Cansado M, Bow EJ. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses. 2017;60(2):79-88.
4. Salzer HJ, **Cornely OA**. Awareness of predictors of mortality may help improve outcome in chronic pulmonary aspergillosis. The European respiratory journal. 2017;49(2).
5. Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekule A, Keller P, Kiehl M, Krause SW, Kramer C, Neumann S, Rohde H, La Rosee P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, **Cornely OA**, Vehreschild MJ. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study. International journal of antimicrobial agents. 2017;49(2):218-23.
6. Hassler A, Lieb A, Seidel D, Cesaro S, Greil J, Klimko N, Khostelidi S, Solopova G, Ogunc D, Duran Graeff L, **Cornely OA**, Vehreschild MJ, Lehrnbecher T. Disseminated Fusariosis in Immunocompromised Children-Analysis of Recent Cases Identified in the Global Fungiscope Registry. Pediatr Infect Dis J. 2017;36(2):230-1.
7. Duran Graeff L, Seidel D, Vehreschild MJ, Hamprecht A, Kindo A, Racil Z, Demeter J, De Hoog S, Aurbach U, Ziegler M, Wisplinghoff H, **Cornely OA**, FungiScope G. Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry. Mycoses. 2017 Feb 2 [Epub ahead of print].
8. Wiesmuller GA, Heinzow B, Aurbach U, Bergmann KC, Bufe A, Buzina W, **Cornely OA**, Engelhart S, Fischer G, Gabrio T, Heinz W, Herr CEW, Kleine-Tebbe J, Klimek L, Koberle M, Lichtnecker H, Lob-Corzilius T, Merget R, Mulleneisen N, Nowak D, Rabe U, Raulf M, Seidl HP, Steiss JO, Szewczyk R, Thomas P, Valtanen K, Hurrass J. Medical Diagnostics for Mold Exposure Indoors. Pneumologie. 2016;70(11):699-741.
9. Vehreschild M, **Cornely OA**. Fecal Microbiota Transfer 2.0. J Infect Dis. 2016;214(2):169-70.
10. Thompson GR, 3rd, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, Maher R, Lee M, Kovanda L, Engelhardt M, Vazquez JA, **Cornely OA**, Perfect JR. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis. 2016;63(3):356-62.
11. Smith IM, Hartmann S, Kessel J, Vehreschild J, **Cornely O**, Rickerts V. Identification of Mycosis Pathogens from Formalin Blocks of Patients with confirmed Fungal Infection with broad-range PCR. Mycoses. 2016;59:5-.
12. Simon ST, Kloke M, Alt-Epping B, Gartner J, Hellmich M, Hein R, Piel M, **Cornely OA**, Nauck F, Voltz R. Effendys - Fentanyl buccal tablet for the relief of episodic breathlessness in patients with advanced cancer: a multicenter, open label, randomized, morphine-controlled, crossover, phase II trial. Journal of pain and symptom management. 2016 Nov;52(5):617-625.
13. Seidel D, Graeff LD, Vehreschild MJG, Liss B, Kohler P, Muller F, Wisplinghoff H, Vehreschild JJ, **Cornely O**. FungiScope (TM) - Global Registry for rare invasive Fungal Infections. Mycoses. 2016;59:10-.

14. Schweer KE, Jakob B, Liss B, Christ H, Fischer G, Vehreschild M, **Cornely OA**, Vehreschild JJ. Domestic mould exposure and invasive aspergillosis-air sampling of *Aspergillus* spp. spores in homes of hematological patients, a pilot study. *Med Mycol*. 2016;54(6):576-83.
15. Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, **Cornely OA**, Vehreschild MJ. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. *Oncoimmunology*. 2016;5(6):e1150399.
16. Pana ZD, Seidel D, Skiada A, Groll AH, Petrikos G, **Cornely OA**, Roilides E, Collaborators Zygomycosis net F. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. *BMC Infect Dis*. 2016;16:9.
17. Marty FM, Ostrosky-Zeichner L, **Cornely OA**, Mullane KM, Perfect JR, Thompson GR, 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Racil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JA, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJ, Vital, FungiScope Mucormycosis I. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infect Dis*. 2016;16(7):828-37.
18. Maertens JA, Raad, II, Marr KA, Patterson TF, Kontoyiannis DP, **Cornely OA**, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet*. 2016;387(10020):760-9.
19. Liss B, **Cornely OA**, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-ss-D-glucan concentrations in blood products predict false positive post-transfusion results. *Mycoses*. 2016;59(1):39-42.
20. Liss B, **Cornely OA**, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-D-Glucan contamination of common antimicrobials. *J Antimicrob Chemother*. 2016;71(4):913-5.
21. Liss B, **Cornely OA**, Hoffmann D, Dimitriou V, Wisplinghoff H. 1,3-beta-d-Glucan contamination of common antimicrobials-authors' response. *J Antimicrob Chemother*. 2016;71(10):2997-9.
22. Liss B, **Cornely OA**. Burden and benefit of antibiotic prophylaxis in cancer chemotherapy. *Lancet Infect Dis*. 2016;16(6):640.
23. Koehler P, Tacke D, **Cornely OA**. Bone and joint infections by Mucorales, *Scedosporium*, *Fusarium* and even rarer fungi. *Crit Rev Microbiol*. 2016;42(1):158-71.
24. Koehler P, **Cornely OA**. Contemporary Strategies in the Prevention and Management of Fungal Infections. *Infect Dis Clin North Am*. 2016;30(1):265-75.
25. Hurrass J, Heinzow B, Aurbach U, Bergmann KC, Bufe A, Buzina W, **Cornely OA**, Engelhart S, Fischer G, Gabrio T, Heinz W, Herr CE, Kleine-Tebbe J, Klimek L, Koberle M, Lichtnecker H, Lob-Corzilius T, Merget R, Mulleneisen N, Nowak D, Rabe U, Raulf M, Seidl HP, Steiss JO, Szewczyk R, Thomas P, Valtanen K, Wiesmuller GA. Medical diagnostics for indoor mold exposure. *International journal of hygiene and environmental health*. 2016 Dec 5 [Epub ahead of print].
26. Higgins PG, Koehler D, Chan JZ, **Cornely OA**, Fatkenheuer G, Gillis M, Pallen MJ, Tien J, Seifert H, Vehreschild MJ, Millard AD. Draft Genome Sequences of Nine Clinical Isolates of Vancomycin-Resistant Enterococci. *Genome announcements*. 2016;4(4).
27. Hagel S, Fischer A, Ehlermann P, Frank T, Tueffers K, Sturm A, Link A, Demir M, Siebenhaar A, Storr M, Glueck T, Siegel E, Solbach P, Goeser F, Koelbel CB, Lohse A, Luebbert C, Kandzi U, Maier M, Schuerle S, Lerch MM, Tacke D, **Cornely OA**, Stallmach A, Vehreschild M, German Clinical Microbiome Study G. Fecal Microbiota Transplant in Patients With Recurrent *Clostridium Difficile* Infection. *Dtsch Arztebl Int*. 2016;113(35-36):583-9.
28. Graeff LAD, Seidel D, **Cornely OA**, Vehreschild MJ, Wisplinghoff H, Lass-Flörl C, de Almeida JN, Hennequin C. The Trichosporosis Collaborative Project. *Mycoses*. 2016;59:11-.

29. Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, **Cornely OA**, Buitrago M, Best E, Sambol S, Osmolski JR, Kracker H, Locher HH, Charef P, Wilcox M. Susceptibility of *Clostridium difficile* isolates from a Phase 2 clinical trial of cadazolid and vancomycin in *C. difficile* infection. J Antimicrob Chemother. 2016;71(1):213-9.
30. Fischer J, Hamacher L, Fries J, Hallek M, **Cornely OA**, Kochanek M, Boell B. *Rhodotorula mucilaginosa* as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL. Ann Hematol. 2016;95(9):1569-70.
31. Farowski F, **Cornely OA**, Hartmann P. High Intracellular Concentrations of Posaconazole Do Not Impact on Functional Capacities of Human Polymorphonuclear Neutrophils and Monocyte-Derived Macrophages In Vitro. Antimicrobial agents and chemotherapy. 2016;60(6):3533-9.
32. **Cornely OA**, Vehreschild MJ. Editorial Commentary: Where to Place the New Treatments for *Clostridium difficile* Infection? Clin Infect Dis. 2016;63(6):735-6.
33. **Cornely OA**, Maher RM, Marty FM, Lee M, Vehreschild JJ, Vehreschild MJ. The VITAL study: case control studies are hypothesis-generating - Authors' reply. Lancet Infect Dis. 2016;16(8):886-7.
34. **Cornely OA**, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jimenez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(6):1747.
35. **Cornely OA**, Duarte RF, Haider S, Chandrasekar P, Helfgott D, Jimenez JL, Candoni A, Raad I, Laverdiere M, Langston A, Kartsonis N, Van Iersel M, Connelly N, Waskin H. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(3):718-26.
36. **Cornely OA**. Mucormycosis - State-of-Art. Mycoses. 2016;59:7-.
37. Boch T, Spiess B, **Cornely OA**, Vehreschild JJ, Rath PM, Steinmann J, Heinz WJ, Hahn J, Krause SW, Kiehl MG, Egerer G, Liebrechts T, Koldehoff M, Klein M, Nolte F, Mueller MC, Merker N, Will S, Mossner M, Popp H, Hofmann WK, Reinwald M, Buchheidt D. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-beta-D-glucan, *Aspergillus* PCR, multifungal DNA-microarray, and *Aspergillus* azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. Clin Microbiol Infect. 2016 Oct;22(10):862-868.
38. Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, Bucker V, Wisplinghoff H, Scheid C, **Cornely OA**, Vehreschild MJ. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71(9):2634-41.
39. Biehl LM, Schmidt-Hieber M, Liss B, **Cornely OA**, Vehreschild MJ. Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients - Review of the literature from a clinical perspective. Crit Rev Microbiol. 2016;42(1):1-16.
40. Ahmed S, Khan Z, Wang XW, Moussa TAA, Al-Zahrani HS, Almaghrabi OA, Sutton DA, Ahmad S, Groenewald JZ, Alastruey-Izquierdo A, van Diepeningen A, Menken SBJ, Najafzadeh MJ, Crous PW, **Cornely O**, Hamprecht A, Vehreschild M, Kindo AJ, de Hoog GS. Chaetomium-like fungi causing opportunistic infections in humans: a possible role for extremotolerance. Fungal Divers. 2016;76(1):11-26.
41. Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Bruggemann RJ, Chowdhary A, **Cornely OA**, Denning DW, Groll AH, Izumikawa K, Kullberg BJ, Lagrou K, Maertens J, Meis JF, Newton P, Page I, Seyedmousavi S, Sheppard DC, Viscoli C, Warris A, Donnelly JP. International expert opinion on the management of infection caused by azole-resistant *Aspergillus fumigatus*. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2015;21-22:30-40.
42. Vehreschild MJ, **Cornely OA**. [Resistant fungi]. Internist (Berl). 2015;56(11):1271-6.
43. Tacke D, Wisplinghoff H, Kretzschmar A, Farowski F, Koehler P, Herweg J, **Cornely OA**, Vehreschild MJ. First implementation of frozen, capsulized faecal microbiota transplantation

- for recurrent *Clostridium difficile* infection into clinical practice in Europe. Clin Microbiol Infect. 2015;21(11):e82-4.
44. Steinmann J, Hamprecht A, Vehreschild MJ, **Cornely OA**, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015;70(5):1522-6.
 45. Stader F, Wuerthwein G, Groll AH, Vehreschild JJ, **Cornely OA**, Hempel G. Physiology-based pharmacokinetics of caspofungin for adults and paediatrics. Pharmaceutical research. 2015;32(6):2029-37.
 46. Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, **Cornely OA**. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol. 2015;94(9):1441-50.
 47. Mendling W, Friese K, Mylonas I, Weissenbacher ER, Brasch J, Schaller M, Mayser P, Effendy I, Ginter-Hanselmayer G, Hof H, **Cornely O**, Ruhnke M. Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013). Geburtshilfe und Frauenheilkunde. 2015;75(4):342-54.
 48. Mendling W, Brasch J, **Cornely OA**, Effendy I, Friese K, Ginter-Hanselmayer G, Hof H, Mayser P, Mylonas I, Ruhnke M, Schaller M, Weissenbacher ER. Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis). Mycoses. 2015;58 Suppl 1:1-15.
 49. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, **Cornely OA**, Heinz WJ, Jagannatha S, Koh LP, Kontoyannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81-9.
 50. Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, **Cornely OA**. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with *Clostridium difficile* Infection. Antimicrobial agents and chemotherapy. 2015;59(10):6266-73.
 51. Knitsch W, Vincent JL, Utzolino S, Francois B, Dinya T, Dimopoulos G, Ozgunes I, Valia JC, Eggimann P, Leon C, Montravers P, Phillips S, Tweddle L, Karas A, Brown M, **Cornely OA**. A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections. Clin Infect Dis. 2015;61(11):1671-8.
 52. Heimann SM, Vehreschild MJ, **Cornely OA**, Franke B, von Bergwelt-Baildon M, Wisplinghoff H, Kron F, Scheid C, Vehreschild JJ. A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation. European journal of haematology. 2015;94(6):526-31.
 53. Heimann SM, Vehreschild JJ, **Cornely OA**, Wisplinghoff H, Hallek M, Goldbrunner R, Bottiger BW, Goeser T, Holscher A, Baldus S, Muller F, Jazmati N, Wingen S, Franke B, Vehreschild MJ. Economic burden of *Clostridium difficile* associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection. 2015;43(6):707-14.
 54. Heimann SM, **Cornely OA**, Wisplinghoff H, Kochanek M, Stippel D, Padosch SA, Langebartels G, Reuter H, Reiner M, Vierzig A, Seifert H, Vehreschild MJ, Glossmann J, Franke B, Vehreschild JJ. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole. Eur J Clin Microbiol Infect Dis. 2015;34(2):331-8.
 55. Glockner A, **Cornely OA**. *Candida glabrata* - unique features and challenges in the clinical management of invasive infections. Mycoses. 2015;58(8):445-50.
 56. Fatkenheuer G, **Cornely OA**, Kern WV, Salzberger B, Stallmach A, Welte T. [Perspectives of infectious diseases in Germany]. Dtsch Med Wochenschr. 2015;140(3):210-2.

57. **Cornely OA**, Meems L, Herbrecht R, Viscoli C, van Amsterdam RG, Ruhnke M. Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses. 2015;58(1):58-64.
58. **Cornely OA**, Gachot B, Akan H, Bassetti M, Uzun O, Kibbler C, Marchetti O, de Burghgraeve P, Ramadan S, Pylkkanen L, Ameye L, Paesmans M, Donnelly JP, Group EID. Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 2015;61(3):324-31.
59. **Cornely OA**, Bohme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrobial agents and chemotherapy. 2015;59(4):2078-85.
60. Bow EJ, Vanness DJ, Slavin M, Cordonnier C, **Cornely OA**, Marks DI, Pagliuca A, Solano C, Cragin L, Shaul AJ, Sorensen S, Chambers R, Kantecki M, Weinstein D, Schlamm H. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis. 2015;15:128.
61. Boch T, Reinwald M, Postina P, **Cornely OA**, Vehreschild JJ, Heussel CP, Heinz WJ, Hoenigl M, Eigl S, Lehrnbecher T, Hahn J, Claus B, Lauten M, Egerer G, Muller MC, Will S, Merker N, Hofmann WK, Buchheidt D, Spiess B. Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA-microarray from primary clinical samples. Mycoses. 2015;58(12):735-45.
62. Bacher P, Steinbach A, Kniemeyer O, Hamprecht A, Assenmacher M, Vehreschild MJ, Vehreschild JJ, Brakhage AA, **Cornely OA**, Scheffold A. Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med. 2015;191(3):348-52.
63. Bacher P, Jochheim-Richter A, Mockel-Tenbrink N, Kniemeyer O, Wingenfeld E, Alex R, Ortigao A, Karpova D, Lehrnbecher T, Ullmann AJ, Hamprecht A, **Cornely O**, Brakhage AA, Assenmacher M, Bonig H, Scheffold A. Clinical-scale isolation of the total Aspergillus fumigatus-reactive T-helper cell repertoire for adoptive transfer. Cytotherapy. 2015;17(10):1396-405.
64. Wille S, Tenholte D, **Cornely OA**, Muthen N, Engelmann UH, Mehner J, Eminaga O, Herden J, Schumacher P, Paas J. [Prediction of overactive bladder treatment outcome by using long-term urodynamics.]. Der Urologe Ausg A. 2014.
65. Wille S, Schumacher P, Paas J, Tenholte D, Eminaga O, Muller U, Muthen N, Mehner J, **Cornely O**, Engelmann U. Catheterless long-term ambulatory urodynamic measurement using a novel three-device system. PloS one. 2014;9(5):e96280.
66. Walsh TJ, Skiada A, **Cornely OA**, Roilides E, Ibrahim A, Zaoutis T, Groll A, Lortholary O, Kontoyiannis DP, Petrikos G. Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses. 2014;57 Suppl 3:2-7.
67. Vehreschild MJ, Weitershagen D, Biehl LM, Tacke D, Waldschmidt D, Tox U, Wisplinghoff H, Bergwelt-Baildon MV, **Cornely OA**, Vehreschild JJ. Clostridium difficile infection in patients with acute myelogenous leukemia and in patients undergoing allogeneic stem cell transplantation: epidemiology and risk factor analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014;20(6):823-8.
68. Vehreschild MJ, von Bergwelt-Baildon M, Tran L, Shimabukuro-Vornhagen A, Wisplinghoff H, Bangard C, **Cornely OA**, Vehreschild JJ. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: A 6-yr analysis from the cologne cohort for neutropenic patients. European journal of haematology. 2014.
69. Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Hantschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, **Cornely**

- OA**, Seifert H. A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. *J Antimicrob Chemother.* 2014;69(12):3387-92.
70. Tacke D, Buchheidt D, Karthaus M, Krause SW, Maschmeyer G, Neumann S, Ostermann H, Penack O, Rieger C, Ruhnke M, Sandherr M, Schweer KE, Ullmann AJ, **Cornely OA**. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. *Ann Hematol.* 2014;93(9):1449-56.
 71. Stader F, Wuerthwein G, Groll AH, Vehreschild J, **Cornely OA**, Hempel G. Physiology-Based Pharmacokinetics of Caspofungin for Adults and Paediatrics. *Pharmaceutical research.* 2014.
 72. Spiess B, Postina P, Reinwald M, **Cornely OA**, Hamprecht A, Hoenigl M, Lass-Flörl C, Rath PM, Steinmann J, Miethke T, Lauten M, Will S, Merker N, Hofmann WK, Buchheidt D. Incidence of Cyp51 A key mutations in *Aspergillus fumigatus*-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013. *PLoS one.* 2014;9(7):e103113.
 73. Schweer KE, Wittersheim M, Bangard C, Frank KF, **Cornely OA**. [Chronic pulmonary Aspergillosis. Four exemplary clinical cases and literature overview]. *Dtsch Med Wochenschr.* 2014;139(44):2242-7.
 74. Schweer KE, Bangard C, Hekmat K, **Cornely OA**. Chronic pulmonary aspergillosis. *Mycoses.* 2014;57(5):257-70.
 75. Platten M, Linnemann R, Kummerle T, Jung N, Wyen C, Ehren K, Gravemann S, Gillor D, **Cornely OA**, Fischer J, Lehmann C, Rockstroh JK, Fatkenheuer G, Vehreschild JJ. Clinical course and quality of care in ART-naive patients newly presenting in a HIV outpatient clinic. *Infection.* 2014;42(5):849-57.
 76. Nucci M, Marr KA, Vehreschild MJ, de Souza CA, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, Heinz WJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvao Castro C, Jr., Herbrecht R, Hoenigl M, Harter G, Hermansen NE, Josting A, Pagano L, Salles MJ, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, **Cornely OA**, Anaissie E. Improvement in the outcome of invasive fusariosis in the last decade. *Clin Microbiol Infect.* 2014;20(6):580-5.
 77. Nathwani D, **Cornely OA**, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in *Clostridium difficile* infection. *J Antimicrob Chemother.* 2014;69(11):2901-12.
 78. Maertens J, **Cornely OA**, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN. Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease. *Antimicrobial agents and chemotherapy.* 2014;58(7):3610-7.
 79. Johnson S, Louie TJ, Gerding DN, **Cornely OA**, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM, Polymer Alternative for CDITi. Vancomycin, metronidazole, or tolevamer for *Clostridium difficile* infection: results from two multinational, randomized, controlled trials. *Clin Infect Dis.* 2014;59(3):345-54.
 80. Heimann SM, Vehreschild MJ, Meintker L, Heinz W, Schroeder T, von Bergwelt-Baildon M, **Cornely OA**, Vehreschild JJ. Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany. *Transplant infectious disease : an official journal of the Transplantation Society.* 2014 Dec;16(6):968-74.
 81. Heimann SM, **Cornely OA**, Vehreschild MJ, Glossmann J, Kochanek M, Kreuzer KA, Hallek M, Vehreschild JJ. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis. *Mycoses.* 2014;57(2):90-7.
 82. Ehren K, Hertenstein C, Kummerle T, Vehreschild JJ, Fischer J, Gillor D, Wyen C, Lehmann C, **Cornely OA**, Jung N, Gravemann S, Platten M, Wasmuth JC, Rockstroh JK, Boesecke C, Schwarze-Zander C, Fatkenheuer G. Causes of death in HIV-infected patients from the Cologne-Bonn cohort. *Infection.* 2014;42(1):135-40.

83. Duarte RF, Lopez-Jimenez J, **Cornely OA**, Laverdiere M, Helfgott D, Haider S, Chandrasekar P, Langston A, Perfect J, Ma L, van Iersel ML, Connelly N, Kartsonis N, Waskin H. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrobial agents and chemotherapy. 2014;58(10):5758-65.
84. **Cornely OA**, Vazquez J, De Waele J, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ. Efficacy of micafungin in invasive candidiasis caused by common *Candida* species with special emphasis on non-albicans *Candida* species. Mycoses. 2014;57(2):79-89.
85. **Cornely OA**, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in *Clostridium difficile* infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69(11):2892-900.
86. **Cornely OA**. Invasive Pilzinfektionen: Aspergillose, Candidose, Mucormykose. Drug Res. 2014;64(Suppl 1):S14-5.
87. Buchheidt D, Spiess B, **Cornely OA**, Vehreschild MJ, Hamprecht A, Rath PM, Steinmann J, Gross U, Bader O, Lauten M, Reinwald M, Hofmann WK. [Azole resistance in *Aspergillus fumigatus* - epidemiology and detection in immunocompromised patients in Germany]. Dtsch Med Wochenschr. 2014;139(25-26):1373-6.
88. Bacher P, Kniemeyer O, Schonbrunn A, Sawitzki B, Assenmacher M, Rietschel E, Steinbach A, **Cornely OA**, Brakhage AA, Thiel A, Scheffold A. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal immunology. 2014;7(4):916-28.
89. Arenz D, Hero B, Eichhorst B, Langer M, Pester L, von Tresckow J, Vehreschild JJ, Vehreschild MJGT, **Cornely OA**. Estimating site costs prior to conducting clinical trials. Clin Invest. 2014;4(3):227-34.
90. Wurthwein G, **Cornely OA**, Trame MN, Vehreschild JJ, Vehreschild MJ, Farowski F, Muller C, Boos J, Hempel G, Hallek M, Groll AH. Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrobial agents and chemotherapy. 2013;57(4):1664-71.
91. Vehreschild MJ, Vehreschild JJ, Hubel K, Hentrich M, Schmidt-Hieber M, Christopheit M, Maschmeyer G, Schalk E, **Cornely OA**, Neumann S. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol. 2013;24(5):1189-202.
92. Vehreschild JJ, Morgen G, **Cornely OA**, Hartmann P, Koch S, Kalka-Moll W, Wyen C, Vehreschild MJ, Lehmann C, Gillor D, Seifert H, Kremer G, Fatkenheuer G, Jung N. Evaluation of an infectious disease consultation programme in a German tertiary care hospital. Infection. 2013;41(6):1121-8.
93. Vehreschild JJ, Birtel A, Vehreschild MJ, Liss B, Farowski F, Kochanek M, Sieniawski M, Steinbach A, Wahlers K, Fatkenheuer G, **Cornely OA**. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol. 2013;39(3):310-24.
94. Reinwald M, Spiess B, Heinz WJ, Heussel CP, Bertz H, **Cornely OA**, Hahn J, Lehrnbecher T, Kiehl M, Laws HJ, Wolf HH, Schwerdtfeger R, Schultheis B, Burchardt A, Klein M, Durken M, Claus B, Schlegel F, Hummel M, Hofmann WK, Buchheidt D. *Aspergillus* PCR-Based Investigation of Fresh Tissue and Effusion Samples in Patients with Suspected Invasive Aspergillosis Enhances Diagnostic Capabilities. J Clin Microbiol. 2013;51(12):4178-85.
95. Pagano L, **Cornely OA**, Busca A, Caira M, Cesaro S, Gasbarrino C, Girmenia C, Heinz WJ, Herbrecht R, Lass-Flörl C, Nosari A, Potenza L, Racil Z, Rickerts V, Sheppard DC, Simon A, Ullmann AJ, Valentini CG, Vehreschild JJ, Candoni A, Vehreschild MJ. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127-30.
96. Pagano L, **Cornely O**, Busca A, Caira M, Cesaro S, Gasbarrino C, Girmenia C, Heinz W, Herbrecht R, Lass-Flörl C, Nosari A, Potenza L, Racil Z, Rickerts V, Sheppard D, Simon A, Ullmann A, Valentini C, Vehreschild J, Candoni A, Vehreschild M. Combination therapy of

- Mucormycosis in Hematology: An Analysis of SEIFEM and FUNGISCOPE Register Studies. Internist. 2013;54:73-.
97. Mullane KM, **Cornely OA**, Crook DW, Golan Y, Louie TJ, Miller MA, Josephson MA, Gorbach SL. Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials. American journal of nephrology. 2013;38(1):1-11.
 98. Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, **Cornely OA**, Löffler J, Ruhnke M, investigators Is. Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study. Eur J Clin Microbiol Infect Dis. 2013;32(5):679-89.
 99. Knoll P, Oppermann J, Vehreschild J, Beyer F, Kaulhausen T, Siewe J, Stein G, Otto C, **Cornely O**, Eysel P, Wyen H, Jakob V, Neugebauer E, Zarghooni K. [Rotating physician in CHIR-Net. Evaluation of the curriculum]. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen. 2013;84(12):1062-6.
 100. Glockner A, **Cornely OA**. [Invasive candidiasis in non-neutropenic adults : Guideline-based management in the intensive care unit]. Anaesthesist. 2013;62(12):1003-9.
 101. Farowski F, **Cornely OA**, Vehreschild JJ, Wiesen M, Steinbach A, Vehreschild MJ, Müller C. Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. International journal of antimicrobial agents. 2013;41(4):379-82.
 102. **Cornely OA**, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. J Clin Oncol. 2013;31(19):2493-9.
 103. Vehreschild JJ, Müller C, Farowski F, Vehreschild MJ, **Cornely OA**, Fuhr U, Kreuzer KA, Hallek M, Kohl V. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987-95.
 104. Vehreschild JJ, Moritz G, Vehreschild MJ, Arenz D, Mahne M, Bredenfeld H, Chemnitz J, Klein F, Cremer B, Boll B, Kaul I, Wassmer G, Hallek M, Scheid C, **Cornely OA**. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. International journal of antimicrobial agents. 2012;39(2):130-4.
 105. Vehreschild JJ, Brockelmann PJ, Bangard C, Verheyen J, Vehreschild MJ, Michels G, Wisplinghoff H, **Cornely OA**. Pandemic 2009 influenza A(H1N1) virus infection coinciding with invasive pulmonary aspergillosis in neutropenic patients. Epidemiol Infect. 2012;140(10):1848-52.
 106. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, **Cornely OA**, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18 Suppl 7:53-67.
 107. Rieger CT, **Cornely OA**, Hoppe-Tichy T, Kiehl M, Knoth H, Thalheimer M, Schuler U, Ullmann AJ, Ehlken B, Ostermann H. Treatment cost of invasive fungal disease (Ifd) in patients with acute myelogenous leukaemia (Aml) or myelodysplastic syndrome (Mds) in German hospitals. Mycoses. 2012;55(6):514-20.
 108. Liss BJ, Vehreschild JJ, **Cornely OA**, Hallek M, Fatkenheuer G, Wisplinghoff H, Seifert H, Vehreschild MJ. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection. 2012;40(6):613-9.
 109. Jung N, Kummerle T, Brengelmann SD, Gielen J, Lehmann C, Wyen C, Birtel A, Fischer J, Gillor D, Koch S, Vehreschild JJ, **Cornely OA**, Fatkenheuer G. Liver involvement in HIV-infected patients diagnosed with syphilis. Infection. 2012;40(5):543-7.

110. Hamprecht A, Buchheidt D, Vehreschild JJ, **Cornely OA**, Spiess B, Plum G, Halbsguth TV, Kutsch N, Stippel D, Kahl P, Persigehl T, Steinbach A, Bos B, Hallek M, Vehreschild MJ. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill. 2012;17(36):20262.
111. Farowski F, **Cornely OA**, Vehreschild JJ, Bauer T, Hartmann P, Steinbach A, Vehreschild M, Scheid C, Muller C. Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood. International journal of antimicrobial agents. 2012;39(3):228-31.
112. **Cornely OA**, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin. Clin Infect Dis. 2012;55 Suppl 2:S154-61.
113. **Cornely OA**, Helfgott D, Langston A, Heinz W, Vehreschild JJ, Vehreschild MJ, Krishna G, Ma L, Huyck S, McCarthy MC. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrobial agents and chemotherapy. 2012;56(5):2652-8.
114. **Cornely OA**, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, Grp OPTCS. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281-89.

Full list of Publications https://www.ncbi.nlm.nih.gov/pubmed/?term=Cornely%2C+O*